These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 26376698

  • 1. Low-dose ofatumumab for rituximab-resistant nephrotic syndrome.
    Bonanni A, Rossi R, Murtas C, Ghiggeri GM.
    BMJ Case Rep; 2015 Sep 16; 2015():. PubMed ID: 26376698
    [Abstract] [Full Text] [Related]

  • 2. Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab.
    Vivarelli M, Colucci M, Bonanni A, Verzani M, Serafinelli J, Emma F, Ghiggeri G.
    Pediatr Nephrol; 2017 Jan 16; 32(1):181-184. PubMed ID: 27687621
    [Abstract] [Full Text] [Related]

  • 3. Mycophenolate Mofetil Following Rituximab in Children With Steroid-Resistant Nephrotic Syndrome.
    Basu B, Mahapatra TK, Mondal N.
    Pediatrics; 2015 Jul 16; 136(1):e132-9. PubMed ID: 26101364
    [Abstract] [Full Text] [Related]

  • 4. Sequential maintenance therapy with cyclosporin A and mycophenolate mofetil for sustained remission of childhood steroid-resistant nephrotic syndrome.
    Gellermann J, Ehrich JH, Querfeld U.
    Nephrol Dial Transplant; 2012 May 16; 27(5):1970-8. PubMed ID: 21976740
    [Abstract] [Full Text] [Related]

  • 5. Ofatumumab for the treatment of childhood nephrotic syndrome.
    Wang CS, Liverman RS, Garro R, George RP, Glumova A, Karp A, Jernigan S, Warshaw B.
    Pediatr Nephrol; 2017 May 16; 32(5):835-841. PubMed ID: 28213687
    [Abstract] [Full Text] [Related]

  • 6. Human or Chimeric Monoclonal Anti-CD20 Antibodies for Children with Nephrotic Syndrome: A Superiority Randomized Trial.
    Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, Cravedi P, Lugani F, Antonini F, Prunotto M, Emma F, Angeletti A, Ghiggeri GM.
    J Am Soc Nephrol; 2021 Oct 16; 32(10):2652-2663. PubMed ID: 34544820
    [Abstract] [Full Text] [Related]

  • 7. New and Old Anti-CD20 Monoclonal Antibodies for Nephrotic Syndrome. Where We Are?
    Basu B, Angeletti A, Islam B, Ghiggeri GM.
    Front Immunol; 2022 Oct 16; 13():805697. PubMed ID: 35222385
    [Abstract] [Full Text] [Related]

  • 8. Rituximab in treatment of idiopathic glomerulopathy.
    El-Reshaid K, Sallam HT, Hakim AA, Al-Attiyah R.
    Saudi J Kidney Dis Transpl; 2012 Sep 16; 23(5):973-8. PubMed ID: 22982909
    [Abstract] [Full Text] [Related]

  • 9. Ofatumumab for rituximab-resistant nephrotic syndrome.
    Basu B.
    N Engl J Med; 2014 Mar 27; 370(13):1268-70. PubMed ID: 24670185
    [No Abstract] [Full Text] [Related]

  • 10. Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol.
    Ravani P, Bonanni A, Ghiggeri GM.
    BMJ Open; 2017 Mar 17; 7(3):e013319. PubMed ID: 28314744
    [Abstract] [Full Text] [Related]

  • 11. Adverse events linked with the use of chimeric and humanized anti-CD20 antibodies in children with idiopathic nephrotic syndrome.
    Bonanni A, Calatroni M, D'Alessandro M, Signa S, Bertelli E, Cioni M, Di Marco E, Biassoni R, Caridi G, Ingrasciotta G, Bertelli R, Di Donato A, Bruschi M, Canepa A, Piaggio G, Ravani P, Ghiggeri GM.
    Br J Clin Pharmacol; 2018 Jun 17; 84(6):1238-1249. PubMed ID: 29436729
    [Abstract] [Full Text] [Related]

  • 12. Rituximab and low-dose cyclosporine combination therapy for steroid-resistant focal segmental glomerulosclerosis.
    Suyama K, Kawasaki Y, Miyazaki K, Kanno S, Ono A, Suzuki Y, Ohara S, Hosoya M.
    Pediatr Int; 2016 Mar 17; 58(3):219-223. PubMed ID: 26275234
    [Abstract] [Full Text] [Related]

  • 13. Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial.
    Ravani P, Pisani I, Bodria M, Caridi G, Degl'Innocenti ML, Ghiggeri GM.
    Pediatr Nephrol; 2020 Jun 17; 35(6):997-1003. PubMed ID: 31993781
    [Abstract] [Full Text] [Related]

  • 14. Protracted remission of proteinuria after combined therapy with plasmapheresis and anti-CD20 antibodies/cyclophosphamide in a child with oligoclonal IgM and glomerulosclerosis.
    Ghiggeri GM, Musante L, Candiano G, Bruschi M, Santucci L, Barbano G, Trivelli A, Rivabella L, Gusmano R, Perfumo F.
    Pediatr Nephrol; 2007 Nov 17; 22(11):1953-6. PubMed ID: 17661091
    [Abstract] [Full Text] [Related]

  • 15. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
    Podestà MA, Trillini M, Portalupi V, Gennarini A, Tomatis F, Villa A, Perna A, Rubis N, Remuzzi G, Ruggenenti P.
    Am J Kidney Dis; 2024 Mar 17; 83(3):340-349.e1. PubMed ID: 37777061
    [Abstract] [Full Text] [Related]

  • 16. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
    Li X, Li H, Ye H, Li Q, He X, Zhang X, Chen Y, Han F, He Q, Wang H, Chen J.
    Am J Kidney Dis; 2009 Jul 17; 54(1):51-8. PubMed ID: 19406543
    [Abstract] [Full Text] [Related]

  • 17. Three year outcome of childhood idiopathic nephrotic syndrome under a unified immunosuppressive protocol.
    Hibino S, Uemura O, Nagai T, Yamakawa S, Iwata N, Ito H, Nakano M, Tanaka K.
    Pediatr Int; 2015 Jul 17; 57(1):85-91. PubMed ID: 25225083
    [Abstract] [Full Text] [Related]

  • 18. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome.
    Loeffler K, Gowrishankar M, Yiu V.
    Pediatr Nephrol; 2004 Mar 17; 19(3):281-7. PubMed ID: 14758528
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of tacrolimus versus cyclosporine in children with steroid-resistant nephrotic syndrome: a randomized controlled trial.
    Choudhry S, Bagga A, Hari P, Sharma S, Kalaivani M, Dinda A.
    Am J Kidney Dis; 2009 May 17; 53(5):760-9. PubMed ID: 19268410
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of combined cyclosporin A and mycophenolate mofetil therapy in patients with cyclosporin-resistant focal segmental glomerulosclerosis.
    Segarra Medrano A, Vila Presas J, Pou Clavé L, Majó Masferrer J, Camps Doménech J.
    Nefrologia; 2011 May 17; 31(3):286-91. PubMed ID: 21468162
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.